GENERAL ASSEMBLY OF NORTH CAROLINA SESSION 2023

Η

D

HOUSE BILL DRH10272-NEp-72

Short Title:Diagnostic Imaging Parity.(Public)Sponsors:Representative Belk.Referred to:

1			A BILL TO BE ENTITLED
2			PROVIDE HEALTH COVERAGE PARITY FOR BREAST CANCER
3			C IMAGING.
4	The Gener		mbly of North Carolina enacts:
5			ION 1.(a) G.S. 58-51-57 is recodified as G.S. 58-3-271.
6			ION 1.(b) G.S. 58-65-92 is repealed.
7			ION 1.(c) G.S. 58-67-76 is repealed.
8			ION 2. G.S. 58-3-271, as enacted by Section 1(a) of this act, reads as rewritten:
9	"§ 58-3-27		verage for <u>diagnostic, screening, and supplemental examinations for</u>
10			cancer, including mammograms and other imaging, and cervical cancer
11		screen	0
12	<u>(a)</u>	The fo	llowing definitions apply in this section:
13		<u>(1)</u>	Breast magnetic resonance imaging. – A diagnostic tool that uses a powerful
14			magnetic field, radio waves, and a computer to produce detailed pictures of
15			the structures within the breast.
16		<u>(2)</u>	Breast ultrasound A noninvasive diagnostic tool that uses high-frequency
17			sound waves to produce detailed images of the breast.
18		<u>(3)</u>	Cost-sharing requirement A deductible, coinsurance, copayment, and any
19			maximum limitation on the application of a deductible, coinsurance,
20			copayment, or similar out-of-pocket expense.
21		<u>(4)</u>	Diagnostic examination for breast cancer. – An examination for breast cancer
22			that is determined by the health care provider treating the patient to be
23			medically necessary and appropriate and that may include breast magnetic
24			resonance imaging, breast ultrasound, and diagnostic low-dose
25			mammography to evaluate the abnormality in the breast that meets one of the
26			following criteria:
27			<u>a.</u> Is seen or suspected from a screening examination for breast cancer.
28			b. <u>Is detected by another means of examination.</u>
29		<u>(5)</u>	Low-dose mammography. – A radiologic procedure for the early detection of
30			breast cancer using equipment dedicated specifically for mammography,
31			including a physician's interpretation of the results of the procedure.
32		<u>(6)</u>	Screening of early detection of cervical cancer. – Examinations and laboratory
33			tests used to detect cervical cancer, including conventional PAP smear
34			screening, liquid-based cytology, and human papilloma virus (HPV) detection
35			methods for women with equivocal findings on cervical cytologic analysis



General A	Asseml	oly Of North Carolina	Session 2023	
		that are subject to the approval of and have been	n approved by the United States	
		Food and Drug Administration.	11 7	
	(7)	Supplemental examination for breast cancer.	. – An examination for breas	
	<u>, , , , , , , , , , , , , , , , , , , </u>	cancer that is determined by the health care pr		
		medically necessary and appropriate and that		
		resonance imaging or breast ultrasound to se		
		meets either of the following criteria:	1	
		a. The patient is at increased risk for brea	ast cancer based on the patient's	
		personal or family medical history of b		
		b. The patient has heterogeneously or ex		
		defined by the Breast Imaging Reportin		
		by the American College of Radiology		
(a) (b)	Every	policy or contract of accident or health insurance		
		r G.S. 58-50-56, that is issued, renewed, or amen		
-		n offered by an insurer in this State shall provide	•	
		for the screening for the early detection of cer	0	
	screening mammography. The same deductibles, coinsurance, and other limitations as apply to similar services covered under the policy, contract, or plan shall apply to coverage for			
	examinations and laboratory tests for the screening for the early detection of cervical cancer and			
		ng mammography.		
(a1)		ed in this section, "examinations and laboratory	y tests for the screening for th	
· · ·		of cervical cancer" means conventional PAP		
cytology, and human papilloma virus (HPV) detection methods for women with equivocal findings on cervical cytologic analysis that are subject to the approval of and have been approved				
		ates Food and Drug Administration.	ovar of and have been approved	
(b)			nography" means a radiologi	
(b) As used in this section, "low dose screening mammography" means a radiologic procedure for the early detection of breast cancer provided to an asymptomatic woman using				
-	equipment dedicated specifically for mammography, including a physician's interpretation of the			
results of			physician's interpretation of an	
(c)		health benefit plan offered by an insurer in this	State that provides benefits for	
		supplemental examination for breast cancer sha		
-		licable to a diagnostic or supplemental examinat		
-		the cost-sharing requirements applicable to a sci		
cancer.	tiluii ti	te cost sharing requirements appreade to a set	recting examination for breat	
<u>eancer:</u> (c)(d)	Cove	rage for low-dose screening mammography shal	l be provided as follows:	
(c) <u>(d)</u>	(1)	One or more mammograms a year, as recomm		
	(1)	woman <u>individual</u> who is at risk for breast		
		subdivision, a woman individual is at risk for b		
		of the following is true:	steast calleer if any one of mor	
		a. The woman individual has a personal h	history of breast cancer: cancer	
		b. The woman individual has a personal h		
		breast disease; disease.	instory of biopsy-proven being.	
		c. The woman's individual's mother, sist	er or daughter has or has ha	
		breast cancer; or <u>cancer.</u>	ter, of daughter has of has had	
		d. The woman has not given birth prior to	a the age of 30.20	
	(2)			
	(2)	One baseline mammogram for any woman	55 through 59 years of age	
	(3)	inclusive; inclusive.	on 10 through 10 years of an	
		A mammogram every other year for any wom	ian 40 unough 49 years of age	
	(\mathbf{J})	inclusive on means fragmentil-	mmandation of a -1!	
	(3)	inclusive, or more frequently upon recon	mmendation of a physician	
	(3)	inclusive, or more frequently upon recor andphysician. A mammogram every year for any woman 50		

	General Assembly Of North Carolina Session 2023				
1	(d)(e) Reimbursement for a mammogram authorized under this section shall be made only				
2	if the facility in which the mammogram was performed meets mammography accreditation				
3	standards established by the North Carolina Medical Care Commission.				
4	(e)(f) Coverage for the screening for the early detection of cervical cancer shall be in				
5	accordance with the most recently published American Cancer Society guidelines or guidelines				
6	adopted by the North Carolina Advisory Committee on Cancer Coordination and Control.				
7	Coverage shall include the examination, the laboratory fee, and the physician's interpretation of				
8	the laboratory results. Reimbursements for laboratory fees shall be made only if the laboratory				
9	meets accreditation standards adopted by the North Carolina Medical Care Commission."				
10	SECTION 3. G.S. 135-48.51 reads as rewritten:				
11	"§ 135-48.51. Coverage and operational mandates related to Chapter 58 of the General				
12	Statutes.				
13	The following provisions of Chapter 58 of the General Statutes apply to the State Health Plan:				
14					
15	(9a) G.S. 58-3-271, Coverage for diagnostic, screening, and supplemental				
16	examinations for breast cancer, including mammograms and other imaging,				
17	and cervical cancer screening.				
18	"				
19	SECTION 4. This act becomes effective October 1, 2023, and applies to insurance				
20	contracts issued, renewed, or amended on or after that date.				